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Abstract
Background: The original version of the International Patient Decision Aid Standards (IPDAS) recommended that
patient decision aids (PtDAs) should be carefully developed, user-tested and open to scrutiny, with a well-
documented and systematically applied development process. We carried out a review to check the relevance and
scope of this quality dimension and, if necessary, to update it.
Methods: Our review drew on three sources: a) published papers describing PtDAs evaluated in randomised
controlled trials and included in the most recent Cochrane Collaboration review; b) linked papers cited in the trial
reports that described how the PtDAs had been developed; and c) papers and web reports outlining the
development process used by organisations experienced in developing multiple PtDAs. We then developed an
extended model of the development process indicating the various steps on which documentation is required, as
well as a checklist to assess the frequency with which each of the elements was publicly reported.
Results: Key features common to all patient decision aid (PtDA) development processes include: scoping and
design; development of a prototype; ‘alpha’ testing with patients and clinicians in an iterative process; ‘beta’ testing
in ‘real life’ conditions (field tests); and production of a final version for use and/or further evaluation. Only about
half of the published reports on the development of PtDAs that we reviewed appear to have been field tested
with patients, and even fewer had been reviewed or tested by clinicians not involved in the development process.
Very few described a distribution strategy, and surprisingly few (17%) described a method for reviewing and
synthesizing the clinical evidence. We describe a model development process that includes all the original
elements of the original IPDAS criterion, expanded to include consideration of format and distribution plans as well
as prototype development.
Conclusions: The case for including each of the elements outlined in our model development process is
pragmatic rather than evidence-based. Optimal methods for ensuring that each stage of the process is carried out
effectively require further development and testing.
Background
The need for a systematic and transparent process for
developing patient decision aids (PtDAs) was recognised in
the original version of the International Patient Decision
Aid Standards (IPDAS) [1]. Specific developmental steps
described in the first iteration of IPDAS were: a) assessing
decisional needs, including analysis of the characteristics of
the decision, specification of treatment options, outcomes
and probabilities, and of patients’ information needs and
their requirements for decisional support; b) formation and
composition of groups to develop and review decision aids;
c) methods for drafting, reviewing and revising these;
d) field testing with patients; and e) external peer review or
critical appraisal by people not involved in its development.
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These steps were originally identified through scrutiny of
55 reports of trials that were included in the second update
of a Cochrane Collaboration review on the effectiveness of
patient decision aids [2], together with accompanying
papers on how these had been developed. However, the
field has moved on since then; many more PtDAs have
been developed and evaluated, including web-based tools,
the Cochrane Collaboration review has been updated and
now includes 86 randomised controlled trials [3], and sev-
eral more groups have published details of their PtDA
development process. We therefore decided to repeat and
update the review to check the currency and relevance of
the original definition and scope of this quality standard.
Theoretical rationale for evaluating patient
decision aids on this quality standard
It is important that PtDAs are carefully developed, user-
tested, and open to scrutiny, with a well-documented and
systematically applied development process. Some decision
aids have been designed for one-off use in studies to
advance knowledge, while others are intended for wider
use in a range of real-life clinical settings. Some have been
developed by academics, some by clinicians, some by
voluntary organizations, and some by commercial compa-
nies. Some developers have produced only one or two
PtDAs, while others have designed processes for produ-
cing them at scale. Whatever their provenance or purpose,
users (clinicians and patients) require assurance that the
development process has been carried out to acceptable
standards. Poor quality decision aids have the potential to
cause harm and they are less likely to advance implemen-
tation of shared decision making more broadly, so it is
essential that users are provided with sufficient documen-
tation to check the validity and reliability of the develop-
ment processes.
Next to validity and reliability, it is also considered
important to involve a range of stakeholders in the devel-
opment process. As well as playing a key role in design of
the PtDA, the involvement of patients, clinicians, and
other relevant experts—for example patient educators,
people with specific expertise in shared decision making,
or policy makers—can facilitate successful implementation
by addressing barriers to delivering or using the PtDA.
Clinicians who do not trust or agree with the content of




Our review focused on descriptions of the PtDA develop-
ment process. We obtained these descriptions from three
main sources: a) published papers describing 86 PtDAs that
had been evaluated in randomised controlled trials and
included in the latest update of the Cochrane Collaboration
review of decision aids [3]; b) linked papers cited in the
trial reports that provided expanded descriptions of how
the PtDAs had been developed; and c) papers and web
reports describing the development process used by a con-
venience sample of organisations that had developed several
decision aids and had published papers or web reports
describing their development process. The checklist we
used to review these descriptions of the PtDA development
process appears in Additional File 1, Appendix 1.
The PtDA development process has been described in a
number of trial reports and associated articles. Many of
the studies included in the Cochrane Collaboration review
gave only cursory descriptions of how their PtDAs had
been developed, but several linked papers provided useful
supplementary detail [5-16] . Many PtDAs reported in the
trials included in the Cochrane Collaboration review were
‘one-offs’ designed for research purposes rather than for
wider distribution, and therefore did not generate insights
into the implementation issues that might have been
addressed during development. However, the experience
of organisations involved in developing series of PtDAs is
helpful for fleshing out the details of what is involved.
Some groups that have developed multiple PtDAs have
proposed guidelines for their development [17-20], or
described insights generated by a particular approach [21].
The following is a brief overview of selected approaches to
decision aid development.
Processes used by experienced PtDA developers
Ottawa Decision Support Framework
O’Connor is among the earliest authors to describe the
development of a PtDA, and the Ottawa Decision Support
Framework (ODSF) guided the development of at least 22
of the PtDAs included in the Cochrane Collaboration
review [10,18]. Based on expectancy value, decisional con-
flict, and social support theories, the framework includes
three key elements: 1) assessment of determinants of
decisions (both patients’ and providers’); 2) provision of
decision support interventions to prepare the patient and
provider to make and implement a decision; and 3) evalua-
tion of the success of the interventions at improving the
quality and outcomes of the decision process. Additional
detail is provided to define determinants of decisions,
such as socio-demographic and clinical characteristics;
patients’ and providers’ perceptions of the decision and
of what important others think about the decision; and
resources (both personal and external) available to
make the decision.
The authors noted that the goals of decision support are
to address modifiable and suboptimal decision determi-
nants, such as inadequate knowledge, unrealistic expecta-
tions, unwanted pressure, and inadequate support. They
encouraged the use of tailored outcome probabilities,
detailed descriptions of benefits and risks, and information
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on the opinions and perspectives of others (both clinicians
and patients) on the decision. Using the example of a deci-
sion aid aimed at helping women decide about use of post-
menopausal hormone therapy, O’Connor outlined an
iterative development process involving the research team
and panels of patients and experts, with the PtDA content
based on clinical guidelines, and structured guidance in
clarifying values and implementing a decision is provided
by a personal worksheet [18].
The Ottawa Framework is particularly relevant to ‘pre-
ference-sensitive’ decisions, which involve careful delibera-
tion and consideration of trade-offs among options.
Perhaps because the PtDA developed by O’Connor was
based on an existing high-quality clinical guideline, the
framework provides little advice for how developers
should review and synthesize the relevant clinical evi-
dence. The framework also does not address how develo-
pers might deal with conflicts of interest, achieving
consensus on the evidence, maintaining the PtDA content
over time, or implementation outside research settings.
Cardiff University
Based on their experience of developing three web-based
PtDAs over a seven-year period, Elwyn and colleagues
proposed a development process for web-based decision
support interventions [17]. This systematic ‘process map’
includes three main steps: 1) content specification, with
an emphasis on ensuring that patients’ perspectives on
the proposed options are sought and included in addition
to synthesis of the scientific evidence; 2) design, including
storyboarding, an iterative phase of trial and experimen-
tation called “sandpit” testing, and usability testing; and
3) field testing with patients facing the decision and clini-
cians who are interacting with them. The process calls
for extensive documentation, including: a protocol docu-
ment that explains the decision and highlights the ratio-
nale for developing a PtDA; evidence synthesis based on
systematic reviews or comprehensive literature searches;
storyboard; and technical specification document to
guide the website development.
The Cardiff projects were overseen by a project manage-
ment group, which retained editorial control, and included
involvement at all steps by key stakeholders including clin-
icians, patients, and policymakers. Unique challenges faced
by developers of web-based tools are highlighted, includ-
ing decisions regarding navigation (free versus mandated)
and use of interactivity (audio, video, gaming, avatars, etc.)
in ways that add value and enhance ease of use yet avoid
over-engineering. The authors found little evidence to
inform best practices in these areas.
The process outlined by Elwyn and colleagues is widely
applicable across a range of situations for which decision
support interventions may be developed (i.e., screening,
treatment, etc.) and a variety of media (although some of
the concepts included, such as storyboarding, are adapted
from film production). However, as the authors acknowl-
edge, the process is time-consuming and costly: three
PtDAs developed using this process each took two to
three years to develop and test. Insights gained from
early efforts could be generalized to create templates to
allow more efficient, less costly future development. The
process outlined does not offer recommendations regard-
ing conflict of interest, processes for achieving consensus
on the evidence, maintenance of PtDA content over time,
or implementation outside research settings.
Dutch Institute for Healthcare Improvement
Researchers at the Dutch Institute for Healthcare Improve-
ment reported on the development over a 12-month per-
iod of 6 decision aids based on existing evidence-based
clinical guidelines [19]. Citing the Ottawa Decision
Support Framework and the IPDAS standards, the authors
followed four key steps: 1) establishment of criteria and
selection of topics; 2) assessment of patients’ information
needs via literature review and focus groups; 3) drafting of
the aid, including iterative review by a multidisciplinary
working group of health professionals, guideline develo-
pers, decision-making experts, and patients, and with refer-
ence to existing aids on the topic; and 4) endorsement of
the aid and establishment of ownership and responsibility
for the maintenance and updating of both the supporting
guideline and the decision aid itself. With regard to imple-
mentation, the authors call for concomitant development
and coordinated release of clinical practice guidelines and
accompanying PtDAs that support their application, and
for identifying and acknowledging early in the guideline
development process any so-called ‘grey zones’ of uncer-
tainty regarding patient preferences.
The outlined process appears efficient and scalable when
high-quality evidence-based practice guidelines are avail-
able. However, the authors acknowledge that additional
research is needed to evaluate the effect of the aids in prac-
tice within the Dutch health care system. The evidence
synthesis step used by other developers is addressed by use
of national evidence-based guidelines; the authors note
that these should also meet internationally accepted quality
criteria, for example the AGREE guidance [22]. The result-
ing tools include a values-clarification method, but the pro-
cess by which the method was selected and ‘populated’
with non-directive, standardized questions is not defined.
Mayo Clinic
Montori and colleagues described insights gleaned from the
pragmatic process they followed to develop the Statin Choice
decision aid for patients with diabetes, which was evaluated
in an RCT included in the Cochrane Collaboration review
[21]. In particular, the authors describe how observations of
clinical interactions during office visits, and of early proto-
types in use during patient-provider encounters, can inform
the ultimate format, design, and content of the final PtDA.
Similar to other developers, their experience reinforces the
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importance of flexibility, iteration, and involvement of
patients and clinicians throughout the process. This article
does not recommend a particular development process, but
rather offers insights unique to the approach their research
group chose. The direct observation methodology that
Montori and colleagues describe may complement more
traditional needs assessment approaches for informing devel-
opers about what patients and physicians need from a PtDA.
Observing early prototypes in the setting they are being
designed for can also be an important step in ensuring that
the intervention will work as intended and have the desired
effect on the decision making process. These insights also
highlight the importance of flexibility during the early stages
of design and development.
Informed Medical Decisions Foundation
Developers that produce PtDAs for both research pur-
poses and for public distribution, such as the Informed
Medical Decisions Foundation (IMDF), provide details of
their development process on their organization’s website
(http://www.informedmedicaldecisions.org). Ten of the
RCTs included in the most recent update of the Cochrane
review used PtDAs developed by this process. IMDF lists
the following elements in their PtDA development pro-
cess: 1) involvement of healthcare providers representing
key clinical specialties, overseen by a clinician who divests
him or herself of any potential financial conflicts of inter-
est; 2) involvement of patients at several stages, including
needs assessment via focus groups and literature reviews;
and 3) review and evaluation of PtDA drafts by providers
and patients prior to their release for general use. The
approach outlines processes for evidence review and
synthesis, disclosure of funding source and conflicts of
interest, and periodic review and updates.
A model development process
Figure 1 illustrates our group’s consensus on the main ele-
ments of a systematic development process based on our
review of relevant literature. While different authors have
placed greater or lesser emphasis on particular aspects,
key features common to all include scoping and design,
development of a prototype, ‘alpha’ testing with patients
and clinicians in an iterative process (testing by people
directly involved in the development process), ‘beta’ testing
in ‘real life’ conditions (field tests with patients and clini-
cians not involved in the development process), and
production of a final version for use and/or further evalua-
tion. The process is often overseen by a multidisciplinary
steering group that includes patient and clinician repre-
sentatives and other relevant stakeholders. The specific
details of how the prototype is developed, in particular
how material for inclusion is reviewed and selected, are
important elements that shape the final product. Less
often mentioned explicitly are choice of format and con-
siderations of how the PtDA will be distributed and made
available to patients and clinicians, yet this seemed to us
to be a crucial part of a design process for a tool intended
for clinical practice.
Further details from our review of the reports included
in the Cochrane Collaboration systematic review are
included in Additional File 2, Table S1, together with
details of the frequency at which the key elements in our
model were reported.
As far as we could tell, few PtDAs evaluated in the
Cochrane Collaboration review had undergone all the steps
outlined in our model during their development. Only
about half appear to have been field tested with patients,
and even fewer had been reviewed or tested by clinicians
not involved in the development process. Inclusion in the
Cochrane Collaboration review meant that all the PtDAs
had been evaluated in randomised controlled trials, but
this type of post-hoc evaluation of impact serves a different
purpose from that of alpha and beta testing during the
development process. Very few developers described a dis-
tribution strategy, and surprisingly few (17%) described a
method for reviewing and synthesizing the clinical evi-
dence. In many cases it was difficult to gauge from the trial
reports whether a development process along the lines
recommended in IPDAS had been followed or not.
Discussion
Despite the proliferation of patient decision aids, detailed
information on the processes by which they were devel-
oped is limited. It was disappointing to find that many of
the PtDA trial reports failed to provide clear information
about how their tools were developed, but it is important
to bear in mind that most of these were developed before
the publication of the IPDAS criteria. A recent study
showed that PtDAs that scored highly on having a sys-
tematic development process also achieved high scores
against other IPDAS criteria [23], but we found no hard
evidence to support the hypothesis that a systematic
development process results in a demonstrably better
gain when using PtDAs in randomised trial or “real life”
conditions. Nevertheless, we believe the case for adopting
a systematic and transparent process is well made.
Our new, more comprehensive model of the develop-
ment process includes all the elements of the original
(see ‘Background’ above), but they have been renamed
and reordered to clarify the different phases of the devel-
opment process. The description of PtDA design has
been expanded to include consideration of format and
distribution plans, and we have also added a section on
prototype development. Our aim was to provide a clearer
overview of the entire development process. However,
this is an overview only, and much uncertainty remains
about the best way to tackle many of the individual ele-
ments. There is little evidence on the relative importance
of each of the features; most have emerged from practical
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experience supported by consensus, but we do not claim
they are evidence-based.
Optimal methods for determining patients’ decisional
needs require further development and testing. Studies
should evaluate how much information patients want or
need and how much detail is required. There is currently
no consensus on how to select material for inclusion in
decision aids, yet the selection process is crucial and fre-
quently debated among those involved. The recent devel-
opment of short-form PtDAs for use within consultations
offers an opportunity to compare the effects of brief
PtDAs against those that are lengthier and more detailed
[24]. There may be scope for closer alignment between
the development of clinical guidelines and PtDAs since
they draw on the same evidence base. This might lead to
greater efficiency in the development process and better
acceptance of PtDAs by clinicians [25].
More guidance is needed to inform PtDA alpha- and
beta- tests, including user-centred design methods,
acceptability, usability, and feasibility testing. While it
is probably unreasonable to expect every PtDA to be
evaluated in an RCT, we believe that all PtDAs should be
subject to user testing at some stage during their devel-
opment. For those developing PtDAs at scale, it may not
be necessary to conduct beta (usability) testing for each
new product once they have designed and tested in a
process that has been shown to work well for patients
and clinicians. Some streamlining to achieve a balance
between rigour and practicality will be essential if the
anticipated demand for PtDAs is to be met.
We would urge PtDA developers to look further afield
for examples of development processes and quality
guidelines that may be instructive, for example guidance
on developing clear communications or user-centred web
Figure 1 Model Development Process for Decision Aids
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design [26,27]. Different formats and delivery mechanisms
also require more evaluation, for example web-based for-
mats with electronic links to clinical record systems. It
makes little sense to embark on the development of a
PtDA without considering the context in which it will be
used and how it will be made available to patients and
clinicians. Better understanding of the barriers and facilita-
tors to adoption of shared decision making and the needs
of the various stakeholders will be essential to ensure suc-
cessful development and implementation of high quality,
useful, and relevant decision aids.
Most PtDA developers aim to produce reliable, unbiased,
clear and comprehensible representations of clinical
options and outcomes that are tailored to patients’ needs
and fit into clinicians’ work flows in a feasible manner, but
their achievement of these goals cannot simply be taken on
trust. Users adopting PtDAs in practice look for evidence
of careful user-testing and clear, transparent documenta-
tion. We have included a suggested template for reporting
key elements in the development process (see Table 1).
Developers might choose to make this information publicly
available on their websites or by other means, or they may
prefer to seek accreditation from a third party. There are
now efforts under way in several countries to develop sys-
tems for certifying patient decision aids as part of regula-
tions supporting widespread use of certified PtDAs in
routine practice. Any accreditation scheme will require a
set of agreed-upon standards and careful documentation of
the processes by which the PtDA was developed. The
IPDAS criteria could form the basis of such schemes. We
hope our suggested model of the development process
will help those wishing to raise standards in decision aid
development.
Additional material
Additional File 1: Appendix 1: Review Checklist
Additional File 2: Table S1: Key Elements of Decision Aid Development
Process
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